Head-to-head evidence
Tadalafil vs Udenafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: PDE5 · full Hypertension pipeline
Tadalafil · Adcirca
Marketed by Eli Lilly
NCT00549302 · Phase 3 · completed
This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy.
Next expected readout: January 2027 · NCT05179876 (registry estimate)
Udenafil · Zydena
Developed by Dong-A ST
NCT02304198 · Phase 2/3 · completed
The study was an open-label, single-group continuation of the randomized DA8159_PAH_II trial, with 59 participants and no concurrent placebo or active comparator. Its primary safety outcome was not reported in the registry, so the primary comparison could not be assessed; the explicit extension design supports a moderate evidence designation despite the lack of blinding and control arm.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tadalafil's landscape · Udenafil's landscape